Lord Abbett & CO. LLC Buys New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Lord Abbett & CO. LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,094,457 shares of the biotechnology company’s stock, valued at approximately $61,858,000.

Other hedge funds also recently made changes to their positions in the company. USA Financial Formulas lifted its position in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 539 shares in the last quarter. Vontobel Holding Ltd. lifted its position in ADMA Biologics by 7.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after buying an additional 888 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics during the 3rd quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 1,509 shares in the last quarter. Finally, Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter valued at about $31,000. 75.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the subject of several recent research reports. Raymond James increased their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Trading Down 0.4 %

ADMA Biologics stock opened at $18.59 on Friday. The stock has a 50-day simple moving average of $19.02 and a 200 day simple moving average of $16.05. The stock has a market capitalization of $4.39 billion, a P/E ratio of 66.39 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52 week low of $3.95 and a 52 week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period in the previous year, the company posted $0.01 EPS. Analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.